The original strain (Enterococcus faecium NCIMB 10415) was isolated in a healthy newborn baby in Sweden in the sixties, and selected for further use thanks to its favorable probiotic characteristics. The pharmacological properties and safety profile of SF68® have been studied extensively and its efficacy confirmed in many double-blind clinical trials.
It has been marketed since decades as hard gelatin capsules in many different markets and is available for distribution under license in several other markets. In Switzerland and Austria, since many years, the product has been and still is no. 1 in the IMS class A7F (Antidiarrheal Microorganisms).
USE
Prevention and treatment of intestinal disorders, such as:
- Treatment of acute diarrhea
- Prevention and treatment of diarrhea due to antibiotic therapy
- Prevention and treatment of travelers’ diarrhea, summer diarrhea and diarrhea due to dietary changes
Hard gelatin capsules in glass bottles.
Depending on the market, products are registered as 10, 20 or 25 capsules per bottle.
SF68® is a registered trademark owned by Cerbios-Pharma SA.
The strain deposit of Enterococcus faecium NCIMB 10415 in the National Collections of Industrial Food and Marine Bacteria in Aberdeen, Scotland, belongs to Cerbios-Pharma SA.
Market
Status
Trademark
Marketer
Mexico
Registered
–
Available for licensing
Canada
Registered
–
Available for licensing
Brasil
Under registration
–
–
Literature
For more information see:
- Holzapfel, W., A. Arini, M. Aeschbacher, R. Coppolecchia and B. Pot. 2018. Enterococcus faecium SF68 as a model for efficacy and safety evaluation of pharmaceutical probiotics. Beneficial Microbes 9(3): 375-388.
